Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Mar;43(3):264–267. doi: 10.1136/jnnp.43.3.264

Oxiperomide in tardive dyskinesia.

D E Casey, J Gerlach
PMCID: PMC490519  PMID: 7373324

Abstract

Tardive dyskinesia can be suppressed by dopaminergic receptor blockers, but often at the cost of a reciprocal increase in Parkinsonism. Oxiperomide, a dopaminergic antagonist that has been shown to reduce levodopa-induced dyskinesias without producing an equal aggravation of Parkinsonism, was evaluated in a blind placebo-controlled trial in 10 patients with tardive dyskinesia. It decreased tardive dyskinesia significantly (p less than 0.01) without significantly provoking or increasing Parkinsonism. There was no relationship between either tardive dyskinesia or Parkinsonism and eye blinking rates. These results can be interpreted as additional evidence for the existence of more than one population of dopamine receptors involved in controlling extrapyramidal function. Although oxiperomide is only a palliative suppressing agent in tardive dyskinesia, as the symptoms returned when the drug was stopped, it is an interesting agent in the search for selective dopaminergic receptor blockers.

Full text

PDF
264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bédard P., Parkes J. D., Marsden C. D. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. Br Med J. 1978 Apr 15;1(6118):954–956. doi: 10.1136/bmj.1.6118.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casey D. E., Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berl) 1977 Aug 31;54(1):1–8. doi: 10.1007/BF00426532. [DOI] [PubMed] [Google Scholar]
  3. Casey D. E., Gerlach J., Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology (Berl) 1979;66(1):73–77. doi: 10.1007/BF00431993. [DOI] [PubMed] [Google Scholar]
  4. Claveria L. E., Teychenne P. F., Calne D. B., Haskayne L., Petrie A., Pallis C. A., Lodge-Patch I. C. Tardive dyskinesia treated with pimozide. J Neurol Sci. 1975 Apr;24(4):393–401. doi: 10.1016/0022-510x(75)90165-3. [DOI] [PubMed] [Google Scholar]
  5. Cools A. R., Van Rossum J. M. Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia. 1976 Feb 2;45(3):243–254. doi: 10.1007/BF00421135. [DOI] [PubMed] [Google Scholar]
  6. Costall B., Naylor R. J. Cholinergic modification of abnormal involuntary movements induced in the guinea-pig by intrastriatal dopamine. J Pharm Pharmacol. 1975 Apr;27(4):273–275. doi: 10.1111/j.2042-7158.1975.tb10698.x. [DOI] [PubMed] [Google Scholar]
  7. Gerlach J., Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl) 1978 Oct 31;59(2):105–112. doi: 10.1007/BF00427742. [DOI] [PubMed] [Google Scholar]
  8. Gerlach J. Tardive dyskinesia. Dan Med Bull. 1979 Aug;26(5):209–245. [PubMed] [Google Scholar]
  9. Kazamatsuri H., Chien C., Cole J. O. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972 Jul;27(1):100–103. doi: 10.1001/archpsyc.1972.01750250086012. [DOI] [PubMed] [Google Scholar]
  10. Klawans H. L., Jr, Weiner W. J. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):427–430. doi: 10.1136/jnnp.37.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marsden C. D. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias). Mod Trends Neurol. 1975;6:141–166. [PubMed] [Google Scholar]
  12. Stevens J. R. Eye blink and schizophrenia: psychosis or tardive dyskinesia? Am J Psychiatry. 1978 Feb;135(2):223–226. doi: 10.1176/ajp.135.2.223. [DOI] [PubMed] [Google Scholar]
  13. Tarsy D., Parkes J. D., Marsden C. D. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry. 1975 Apr;38(4):331–335. doi: 10.1136/jnnp.38.4.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Webster D. D. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 Mar;5(2):257–282. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES